Skip to main content

Table 2 Nanomedicines in clinical trials

From: Cancer nanomedicine: a review of recent success in drug delivery

Year Name Type of nano-particle Active drug Phase of trial Size (nm) Type of cancer References
2017 NU-0129 Gold Gold and siRNAs I * Glioblastoma multiforme [89, 90]
2017 MM-398 Liposome Irinotecan I, II, III 80–140 Small cell lung cancer, metastatic pancreatic adenocarcinoma, pediatric solid tumors [70, 88, 91, 92]
2016* Genexol-PM Polymer Paclitaxel I/II < 50 Gynecologic cancer, hepatocellular carcinoma, advanced breast cancer, non-small cell lung cancer [93,94,95,96]
2016 CRLX101 Polymer Camptothecin I/II 30–40 Ovarian, rectal, renal, fallopian tube, lung (small cell and non-small cell) primary peritoneal, stomach, gastroesophageal, and esophageal cancers [71, 72, 89, 97,98,99,100,101, 127]
2016 AuroLase Silica-Gold Gold I 150 Prostate, head and neck, lung [73, 102, 103]
2016 Vincristine sulfate liposome injection Liposome Vincristine I/II ~ 100 Kaposiform hemangioendotheloma, Kasabach–Merritt Syndrome, tufted angioma, rhabdomyosarcoma, recurrent adult acute myeloid leukemia, lymphoblastic leukemia***, multiple lymphomas (non-hodgkin, follicular, mantle-cell, small-cell, and B-cell [Margional Zone]), Waldenstrom macroglobulinemia [87, 104,105,106,107,108]
2016 Anti-EGFR immuno-liposome Liposome Doxorubicin II 130–200 Breast cancer [74, 109, 110]
2015 Mitoxantrone HCl liposome injection (plm60-s) Liposome Mitoxantrone II 60 Breast cancer, diffuse large B-cell lymphoma, non-Hodgkin’s lymphoma, and peripheral T/NK lymphomas [75, 111,112,113,114]
2014 CPX-351 Liposome   I * Acute myeloid leukemia [115]
2014 LipoCURC Liposome Curcumin I/II * Advanced cancer with failed standard of care therapy [116]
2014 SGT-53 Liposome Plasmid containing normal human wild type p53 DNA I/II * Glioblastoma, neoplasm, metastatic pancreatic cancer [117,118,119,120]
2013 LiPlaCis Liposome Cisplatin I/II * Advanced or refractory solid tumours, metastatic breast cancer [121, 122]
2012 PROMITIL Liposome Mitomycin-C I ~ 90 Solid tumors [123, 124]
2011 Abraxane Protein-drug conjugate Paclitaxel II ~ 130 Breast cancer** [125]
  1. * Information not provided
  2. ** All patients are over the age of 65; breast cancers include estrogen receptor negative/positive, male breast cancer, Her2-negative/positive breast cancer, progesterone receptor positive/negative breast cancer, and several others
  3. *** Patients were between age 1–21